CA2749126C - Conjugues oligomere-phenothiazine - Google Patents

Conjugues oligomere-phenothiazine Download PDF

Info

Publication number
CA2749126C
CA2749126C CA2749126A CA2749126A CA2749126C CA 2749126 C CA2749126 C CA 2749126C CA 2749126 A CA2749126 A CA 2749126A CA 2749126 A CA2749126 A CA 2749126A CA 2749126 C CA2749126 C CA 2749126C
Authority
CA
Canada
Prior art keywords
oligomer
promethazine
group
phenothiazine
dcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2749126A
Other languages
English (en)
Other versions
CA2749126A1 (fr
Inventor
Xuyuan Gu
Jennifer Riggs-Sauthier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CA2749126A1 publication Critical patent/CA2749126A1/fr
Application granted granted Critical
Publication of CA2749126C publication Critical patent/CA2749126C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne (entre autres) des conjugués oligomère-phénothiazine et des composés associés. Un conjugué selon l'invention, lorsqu'il est administré par une quelconque parmi une pluralité de voies d'administration, présente des avantages par rapport aux composés de phénothiazine non conjugués.
CA2749126A 2009-01-28 2010-01-28 Conjugues oligomere-phenothiazine Active CA2749126C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14801609P 2009-01-28 2009-01-28
US61/148,016 2009-01-28
PCT/US2010/022342 WO2010088340A1 (fr) 2009-01-28 2010-01-28 Conjugués oligomère-phénothiazine

Publications (2)

Publication Number Publication Date
CA2749126A1 CA2749126A1 (fr) 2010-08-05
CA2749126C true CA2749126C (fr) 2017-08-22

Family

ID=42101449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749126A Active CA2749126C (fr) 2009-01-28 2010-01-28 Conjugues oligomere-phenothiazine

Country Status (8)

Country Link
US (3) US20120046279A1 (fr)
EP (1) EP2391386B1 (fr)
JP (1) JP5828587B2 (fr)
CN (1) CN102300588B (fr)
AU (1) AU2010208274B2 (fr)
CA (1) CA2749126C (fr)
MX (1) MX2011007940A (fr)
WO (1) WO2010088340A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005813A (es) * 2007-11-28 2010-06-15 Nektar Therapeutics Conjugados oligomero-triciclicos.
CA2749126C (fr) 2009-01-28 2017-08-22 Nektar Therapeutics Conjugues oligomere-phenothiazine
WO2011091050A1 (fr) * 2010-01-19 2011-07-28 Nektar Therapeutics Conjugués oligomères-tricycliques
EP2758403B1 (fr) 2011-09-21 2016-04-27 Inception Orion, Inc. Composés tricycliques utiles comme agents neurogènes et neuroprotecteurs
JP6265998B2 (ja) 2012-09-17 2018-01-24 ネクター セラピューティクス オリゴマー含有ベンズアミド系化合物
US9695138B1 (en) * 2016-10-17 2017-07-04 Acenda Pharma, Inc. Phenothiazine derivatives and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2530451A (en) 1950-11-21 Phenothiazines
US2519886A (en) 1950-08-22 Beta-bimethylaminoethylphenothia
US2607773A (en) 1952-08-19 Processes for preparing phenthi-
GB641452A (en) 1946-12-09 1950-08-09 Rhone Poulenc Sa Improvements in or relating to the preparation of derivatives of phenthiazine
US3987042A (en) 1969-03-03 1976-10-19 Claude Gueremy Phenothiazine derivative
FR2632521B1 (fr) 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1360180A1 (fr) 2001-01-19 2003-11-12 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
WO2003002150A1 (fr) 2001-06-28 2003-01-09 Wyeth Composition et procede permettant de reduire des interactions nefastes entre des derives de phenothiazine et du plasma
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
CA2758460C (fr) 2003-12-16 2014-09-23 Nektar Therapeutics Methodes de preparation de compositions de reactifs oligo (ethylene glycol) monodisperses
US20080112257A1 (en) * 2006-11-10 2008-05-15 Masatoshi Masuda Mixing device for tub
EP2121031B1 (fr) * 2007-03-12 2013-10-16 Nektar Therapeutics Conjugués d'oligomère antihistaminique
CA2749126C (fr) 2009-01-28 2017-08-22 Nektar Therapeutics Conjugues oligomere-phenothiazine

Also Published As

Publication number Publication date
EP2391386A1 (fr) 2011-12-07
US20120046279A1 (en) 2012-02-23
MX2011007940A (es) 2011-08-15
US10485877B2 (en) 2019-11-26
CA2749126A1 (fr) 2010-08-05
CN102300588A (zh) 2011-12-28
JP2012516347A (ja) 2012-07-19
EP2391386B1 (fr) 2018-06-27
US20180243429A1 (en) 2018-08-30
AU2010208274A1 (en) 2011-07-21
JP5828587B2 (ja) 2015-12-09
US20200038517A1 (en) 2020-02-06
CN102300588B (zh) 2014-07-16
WO2010088340A1 (fr) 2010-08-05
AU2010208274B2 (en) 2015-11-05
US10869933B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
US10869933B2 (en) Oligomer-phenothiazine conjugates
JP5827123B2 (ja) 乱用の可能性が低いｐｅｇ化オピオイド
EP2121031B1 (fr) Conjugués d'oligomère antihistaminique
US9314463B2 (en) Oligomer-diarylpiperazine conjugates
US10251959B2 (en) Oligomer-beta blocker conjugates
US10265411B2 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
US9168311B2 (en) Oligomer-dantrolene conjugates and related compounds
US8389759B2 (en) Oligomer-anticholinergic agent conjugates
US20120101145A1 (en) Oligomer-Containing Pyrrolidine Compounds
WO2009054916A2 (fr) Conjugués d'oligomère de lidocaïne et leurs dérivés
EP2400989B1 (fr) Conjugués gabapentine-peg
US20110009446A1 (en) Oligomer-guanidine class conjugates
US20140039020A1 (en) Oligomer-Containing Hydantoin Compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141110